Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Other Non-Current Liabilities (2022 - 2024)

Historic Other Non-Current Liabilities for 60 Degrees Pharmaceuticals (SXTPW) over the last 3 years, with Q1 2024 value amounting to $565949.0.

  • 60 Degrees Pharmaceuticals' Other Non-Current Liabilities fell 6225.33% to $565949.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $565949.0, marking a year-over-year decrease of 6225.33%. This contributed to the annual value of $75000.0 for FY2023, which is 9498.06% down from last year.
  • 60 Degrees Pharmaceuticals' Other Non-Current Liabilities amounted to $565949.0 in Q1 2024, which was down 6225.33% from $75000.0 recorded in Q4 2023.
  • 60 Degrees Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $1.5 million for Q1 2023, and its period low was $75000.0 during Q4 2023.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $1.0 million (2022), whereas its average is $908620.8.
  • Per our database at Business Quant, 60 Degrees Pharmaceuticals' Other Non-Current Liabilities tumbled by 9498.06% in 2023 and then crashed by 6225.33% in 2024.
  • Quarter analysis of 3 years shows 60 Degrees Pharmaceuticals' Other Non-Current Liabilities stood at $1.5 million in 2022, then crashed by 94.98% to $75000.0 in 2023, then skyrocketed by 654.6% to $565949.0 in 2024.
  • Its Other Non-Current Liabilities stands at $565949.0 for Q1 2024, versus $75000.0 for Q4 2023 and $1.5 million for Q1 2023.